Joint ACTRIMS-ECTRIMS Meeting

Expanded Disability Scale Status and age served as independent risk factors for severe COVID-19 infection in a multicenter study of patients with MS and COVID-19 presented during an encore session of MSVirtual2020.

A “high relative abundance” of a gut microbiota species in the Blautia genus correlated with a greater risk for MS relapse in pediatric patients, according to findings presented during an encore session of MSVirtual2020.

Serum neurofilament light chain levels increased during pregnancy and the postpartum period among women with MS in the Swiss MS Cohort study, according to findings presented during an encore session of MSVirtual2020.

A novel allogeneic Epstein-Barr virus-targeted T-cell immunotherapy in early development was well-tolerated and led to sustained disability improvements in patients with progressive forms of MS, researchers reported at MSVirtual2020.

In this video from MSVirtual2020, Helen Tremlett, PhD, professor in the department of medicine at the University of British Columbia and the Canada Research Chair in Neuroepidemiology and Multiple Sclerosis, shares highlights from her talk during the plenary session at MSVirtual2020.

Longer exposure to disease-modifying treatment delayed the time to wheelchair use among patients with primary progressive MS, or PPMS, according to findings presented at MSVirtual2020.

Treatment with masitinib, a first-in-class tyrosine kinase inhibitor, led to significant improvement in Expanded Disability Scale Status, or EDSS, for patients with MS, according to findings presented at MSVirtual2020.

Enspryng lowered relapse severity in patients with neuromyelitis optica spectrum disorder, according to data from the double-masked periods of the SAkura phase 3 studies presented at the MSVirtual2020 meeting.

Low doses of rituximab provided patients with MS an effective treatment option and an improved safety profile compared with higher doses of the agent, according to findings presented at MSVirtual2020.

Women with relapsing-remitting MS who had higher levels of disease activity and were managed on moderate- or high-efficacy therapy were at greater risk for relapse during pregnancy, researchers reported.